Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

BACKGROUND: The efficacy and safety of apremilast were assessed in patients with psoriatic arthritis (PsA) in three phase III clinical trials with similar designs (PALACE 1, 2, and 3). METHODS: Following a 24-week, randomized (1:1:1 to apremilast 30 mg twice daily, 20 mg twice daily, or placebo), do...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Arthritis Res Ther
Hlavní autoři: Kavanaugh, Arthur, Gladman, Dafna D., Edwards, Christopher J., Schett, Georg, Guerette, Benoit, Delev, Nikolay, Teng, Lichen, Paris, Maria, Mease, Philip J.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6509758/
https://ncbi.nlm.nih.gov/pubmed/31077258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-019-1901-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky